A variety of solid tumors harbor alterations in BRCA genes.5-7 In a recent pan-cancer analysis (n = 234; 154 specimens from 408 tumor types), the overall proportion with BRCAmut+ was 4.7%, the highest incidence being found for ovarian (15.2%), prostate (10.7%), skin squamous cell (9.1%), breast (8.8%), endometrial (5.3%), and pancreatic (5.2%) cancers.8 In some indications, including ovarian, breast, and prostate cancers, these alterations have been shown to confer sensitivity to PARP inhibition.9-14. This evidence concerns the gene PARP1 and neoplasm.